拜瑞妥对静脉血栓的效果好吗?
Rivaroxaban is a highly selective, oral drug that directly inhibits factor xa. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited. Clinically indicated for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery.
Xarelto Rivaroxaban Tablets for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery: The recommended dose of Xarelto Rivaroxaban Tablets is 10 mg of rivaroxaban taken orally once daily. If the wound has stopped bleeding, the first dose of medication should be between 6 and 10 hours after surgery. For patients undergoing major hip surgery, the recommended course of treatment is 35 days. For patients undergoing major knee surgery, the recommended course of treatment is 12 days. If a missed dose occurs, the patient should take rivaroxaban immediately and continue taking the dose once daily the next day.
Is Xarelto effective against venous thrombosis? The RECORD1-2 study evaluated the safety and effectiveness of Xarelto in preventing VTE in patients undergoing elective total hip replacement surgery.
The results showed that compared with enoxaparin, Xarelto could significantly reduce the incidence of total VTE, major VTE and symptomatic VTE, while the incidence of major bleeding events and other bleeding events was similar in the two groups. The RECORD3~4 study compared the safety and effectiveness of the above two drugs in preventing venous thromboembolism in patients after elective total knee replacement. The incidence rate of the primary endpoint event in the enoxaparin group was 18.9%, while that of Xarelto was only 9.6%. The difference between the two was statistically significant (P<0.001).
The results showed that the efficacy of the rivaroxaban tablets group was not inferior to traditional treatment, and the risk of bleeding was equivalent to or lower than traditional treatment.
Recommended related hot articles: /newsDetail/81620.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)